Dare Bioscience, Inc. Intellectual Property Contracts & Agreements
16 Contracts & Agreements
- License Agreements (16 contracts)
- First Amendment to License Agreement by and between Organon International GmbH and Dar Bioscience, Inc., entered into as of July 4, 2023 (Filed With SEC on November 9, 2023)
- Amendment No. 3 to the Amended and Restated Exclusive License Agreement, effective as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear... (Filed With SEC on March 30, 2023)
- Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH (Filed With SEC on May 12, 2022)
- Exclusive license agreement by and between Organon International GmbH and Dar Bioscience, Inc., dated as of March 31, 2022 (Filed With SEC on May 12, 2022)
- Amendment to License Agreement effective as of September 21, 2021 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on November 10, 2021)
- Amendment No. 2 to the License Agreement entered into as of December 3, 2019 between Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on March 27, 2020)
- License Agreement dated as of January 10, 2020 between Bayer HealthCare LLC and Dar Bioscience, Inc (Filed With SEC on March 27, 2020)
- First Amendment to the License Agreement effective as of December 5, 2018 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on April 1, 2019)
- Exclusive License Agreement, dated as of September 15, 2017, by and between Fred Mermelstein, Ph.D., Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc., and Stephen C. Rocamboli (Filed With SEC on August 13, 2018)
- Exclusive License Agreement, dated as of February 13, 2017, by and between GYN Holdings, Inc., a wholly owned subsidiary of Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus (Filed With SEC on August 13, 2018)
- Amendment No. 2 to the Amended and Restated Exclusive License Agreement, dated as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree... (Filed With SEC on August 13, 2018)
- Amendment No. 1 to the Amended and Restated Exclusive License Agreement, dated as of October 10, 2007, by and among Fred Mermelstein, Ph.D. and Janet Chollet, M.D., and Pear Tree... (Filed With SEC on August 13, 2018)
- Amended and Restated Exclusive License Agreement, dated as of July 14, 2006, by and between Fred Mermelstein, Ph.D. and Janet Chollet, M.D., and Pear Tree Womens Health Care, Inc (Filed With SEC on August 13, 2018)
- Exclusive License Agreement made as April 24, 2018 by and between Juniper Pharmaceuticals, Inc., and Dar Bioscience, Inc (Filed With SEC on August 13, 2018)
- License Agreement dated March 19, 2017, between Dar Bioscience Operations, Inc. and ADVA-Tec, Inc (Filed With SEC on November 13, 2017)
- LICENSE AGREEMENT (Filed With SEC on March 20, 2017)
